Eukaryotic elongation factor 2 kinase (eEF2K) negatively regulates the elongation phase of mRNA translation and hence protein synthesis. Increasing evidence indicates that eEF2K plays an important role in the survival and migration of cancer cells and in tumor progression. As demonstrated by two-dimensional wound-healing and three-dimensional transwell invasion assays, knocking down or inhibiting eEF2K in cancer cells impairs migration and invasion of cancer cells. Conversely, exogenous expression of eEF2K or knocking down eEF2 (the substrate of eEF2K) accelerates wound healing and invasion. Importantly, using LC-HDMS E analysis, we identify 150 proteins whose expression is decreased and 73 proteins which are increased upon knocking down eEF2K in human lung carcinoma cells. Of interest, 34 downregulated proteins are integrins and other proteins implicated in cell migration, suggesting that inhibiting eEF2K may help prevent cancer cell mobility and metastasis. Interestingly, eEF2K promotes the association of integrin mRNAs with polysomes, providing a mechanism by which eEF2K may enhance their cellular levels. Consistent with this, genetic knock down or pharmacological inhibition of eEF2K reduces the protein expression levels of integrins. Notably, pharmacological or genetic inhibition of eEF2K almost completely blocked tumor growth and effectively prevented the spread of tumor cells in vivo. High levels of eEF2K expression were associated with invasive carcinoma and metastatic tumors. These data provide the evidence that eEF2K is a new potential therapeutic target for preventing tumor metastasis.
Introduction
Tumor metastasis is a hallmark of malignant carcinomas and is associated with poor prognosis and survival rates among high-risk cancer patients. According to the US National Cancer Institute Surveillance, Epidemiology and End Results (SEER) registries, in 2016, the average survival rates from diagnosed metastatic cancer patients are only 25% or less compared to patients suffering localized (organ-defined) or regional (lymph node invasion) cancers. 1 This has not improved much during the last decade. 1, 2 In recent years, regulatory mechanisms driven by versatile molecular signaling pathways controlling protein synthesis have been revealed to play central roles in tumor metastasis and progression. Thus, the capacity of the translation machinery of cancer cells to "fine-tune" gene expression has attracted increasing attention in both basic and translational cancer research fields.
Although global protein synthesis is generally increased in cancer cells, accumulating data indicate that the translational regulatory networks somehow steer events to adapt to microenvironmental stress conditions and satisfy the survival and spreading requirements of such cells. Notably, mTORC1 (mechanistic target of rapamycin complex 1) 3 and its downstream effector eIF4E (eukaryotic translation initiation factor 4E), 4 ,5 a key regulator of translation initiation, are both essential for reshaping the cell translatome to initiate tumorigenesis and metastasis.
Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a very specific, atypical protein kinase whose only validated substrate is eEF2. eEF2 mediates the codon-by-codon translocation of ribosomes along mRNAs and the concomitant movement of aminoacyl-tRNA from A into P site. Phosphorylation of eEF2 by eEF2K on Thr56 6 impedes the binding of eEF2 to ribosomes and hence impairs translation elongation. 7, 8 Interestingly, eEF2K is highly expressed in some cancers such as medulloblastoma, glioblastoma, 9 breast cancer 10 and pancreatic tumors. 11 It is activated under several stress conditions typically present in the tumor microenvironment, e.g. lack of nutrients, 9 hypoxia, 12 acidosis 13 and/or energy deprivation. 14 It has been shown that blocking eEF2K activity renders cancer cells vulnerable to these environmental stresses, 9,12,13 indicating a protective role for eEF2K in cancer cells under these conditions. Forkhead box M1 (FOXM1), 15 miR-603 16 and miR-877 17 were recently found to play roles in tumorigenesis, concomitantly with changes in the expression levels of eEF2K, also suggesting that eEF2K may aid cancer progression. 15, 17 However, prior to our study, it was unclear why control of translation elongation also played roles in tumor cell migration and invasion. In our study, using LC-HDMS E analysis, we show for the first time that eEF2K and hence control of translation elongation act as important regulators of cancer cell metastasis by steering the translation machinery toward producing proteins related to cell migration. We show that genetic and/or pharmacological inhibition of eEF2K decreases cancer cell mobility and the spread of cancer cells in vivo. Our data provide insights into the molecular mechanisms of how translation elongation promotes cancer metastasis.
Material and Methods

Chemicals and reagents
All reagents were from Sigma-Aldrich (Castle Hill, NSW, Australia) unless specified. The Bradford assay reagent was from Bio-Rad (Gladesville, NSW, Australia). IPTG (isopropyl b-D-1-thiogalactopyranoside) was from Promega (Sydney, NSW, Australia). AZD8055 was kindly provided by AstraZeneca (London, UK). The eEF2K inhibitor JAN-384 18 was a kind gift from Janssen Pharmaceutica NV (Beerse, Belgium). Specific pathogen-free BALB/c nude male mice (6 weeks old) were purchased from the Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China). All institutional and national guidelines for the care and use of laboratory animals were followed. For experimental lung metastasis, nude mice were injected with A549 cells (2 3 10 6 cells per mouse) via the tail vein and randomly assigned to control and treatment groups on Day 1. NH125 (1 mg/kg in 1% DMSO, 1% Tween 80 in PBS), A-484954 (2.5 mg/kg in 1% DMSO, 1% Tween 80 in PBS) or control solution (1% DMSO, 1% Tween-80 in PBS) was injected intraperitoneally
What's new?
New results show how a protein involved in translation helps cancer cells travel. Eukaryotic elongation factor 2 (eEF2) moves the ribosome along the mRNA strand, and eEF2K impairs its ability to do this. Previous reports note that many cancers produce copious eEF2K, and that blocking it inhibits cell migration. Here, the authors show that reducing eEF2K in the lung cancer cells cuts expression of some 34 proteins needed for cell migration. They further showed that in mice, inhibiting eEF2K stops the growth and spread of tumors. Targeting eEF2K, they propose, could be a fruitful strategy for thwarting metastasis.
on the following and then every second day. The weight of each mouse was recorded every 5 days.
Lentiviral NT (non-targeting, catalogue No. CON077) and eEF2K (catalogue No. 36048-1) shRNA were from Genechem (Shanghai, China). Nude mice were randomly injected with shNT-infected A549 or sheEF2K-infected A549 cells (2 3 10 6 cells per mouse) via tail veins. After 46 days of treatment, mice were sacrificed and lungs were harvested and fixed in Bouin's solution for photograph; or in 4% paraformaldehyde for haematoxylin and eosin (H&E) staining and immunohistochemical analysis. The number of metastatic nodules in the lung was determined by macroscopic photographs.
Generation of eEF2K-knockout MEFs
The generation of eEF2K-knockout mice was previously described. 12 MEFs (mouse embryonic fibroblasts) from these mice and matched wild-type counterparts were prepared from embryos at embryonic Day 13.5.
SDS-PAGE and western blot analysis
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and western blot analysis were performed as previously described. 19 Supporting Information Table S1 shows a complete list of antibodies used in our study. Data shown are representative of at least three independent experiments.
Polysome analysis
This was performed as described previously. 19 For protein precipitation, 10% TCA (trichloroacetic acid) was added to each of the isolated fractions. Samples were spun at 16,000g and 48C for 10 min, protein pellets were then washed thrice with acetone before dissolved in Laemmli sample buffer [0.1 M Tris-HCl pH 6.8, 2% (w/v) SDS, 4% (v/v) glycerol, 0.024% (w/v) bromophenol blue and 10 mM DTT (1,4-dithiothreitol)] for further analysis.
For RNA extraction, 1% (w/v) SDS and 0.15 mg/ml proteinase K were added to each fractions, 1:3 (v/v) phenol:-chloroform pH 4.5 was then added to the samples to extract RNA, RNA were precipitated from the aqueous phase by the addition of 70% (v/v) isopropanol. RNA pellets were washed once with 80% (v/v) ethanol, before dissolving in RNase/ DNase-free water for further analysis.
Flow cytometry
Cells were trypsinized and incubated with the primary antibodies (1:100, diluted in 0.1% BSA (w/v) in PBS) for 30 min at 48C, cells were washed thrice with PBS and then incubated with Alexa Fluor-conjugated secondary antibodies (Abcam, Melbourne, VIC, Australia) for 30 min. They were washed again thrice with PBS, the intensity of fluorescence signals was recorded using FACSCanto TM II flow cytometry (Becton Dickinson (BD) Biosciences, North Ryde, NSW, Australia), data were analyzed using FlowJo software version 10.2 (BD Biosciences).
Real-time quantitative RT-PCR (qPCR) amplification analysis
Total RNA was extracted using TRIzol (Life Technologies). cDNA was produced using the ImProm-II reverse transcription (RT) system (Promega) with oligo(dT) 15 . For qPCR analysis of sucrose gradient fractions, 1.2 kb kanamycin RNA provided by the RT kit was used as an internal control. qPCR was performed using specific primers in Supporting Information Table S2 . Samples were analyzed with SYBR green dye mix (PrimerDesign, Hampshire, UK) on an ABI
Step One Plus qPCR instrument (Applied Biosystems, Cheshire, UK). For total RNA analysis, 18 S rRNA (HK-SY-hu-600 from PrimerDesign) was used as the normalization control. The comparative threshold cycle (C T ) method was applied to quantify mRNAs present in each samples.
Scratch-wound healing assay
As previously described, 20 30 mm diameter culture dishes containing a monolayer of cells were starved of serum for 16 hr, cells were then immersed in 2 ml growth medium in the presence of 0.5 lg/ll mitomycin C, and scratched using a P-20 pipette tip forming a "wound" across its diameter. Images were taken using a Zeiss Axiovert 200 microscope (310 objective lens) at indicated time points. Images were quantified by ImageJ (version 1.50) software (https://imagej. nih.gov/ij/).
Transwell migration and invasion assay
As previously described, 20 for migration assays, transwells (8 mm pore size, BD Biosciences) were pre-coated with 1% (v/v) gelatin in serum-free medium, assays were then performed with 1.5 3 10 4 cells plus 0.5 lg/ll mitomycin C for 24 hr using 10 lg/ml collagen as chemo-attractant. For invasion assays, transwells were pre-coated with Matrigel (1:3 in DMEM (v/v), BD Biosciences), assays were then performed with 5 3 10 4 cells plus 0.5 lg/ll mitomycin C for 72 hr using 10% FBS as chemo-attractant. Transwells were then stained with DAPI (4 0 ,6-diamidino-2-phenylindole, 1:20,000) and visualized with a Nikon Eclipse Ni microscope (310 objective lens). DAPI-stained cell numbers were quantified by using ImageJ.
Adhesion assay
To assess cell adhesion, we used a modified version of a procedure that was described previously, 21 4 3 10 4 cells
were trypsinized and plated in either gelatin (20 mg/ml in PBS, 2 hr, 378C) or poly-L-lysine (0.1 mg/ml in PBS, 5 min, room temperature) pre-coated plates, and incubated at 378C for 30 min, cells were washed twice with PBS before staining with 1 mM calcein AM (Thermo Fisher Scientific, Scoresby, VIC, Australia) in DMEM for 30 min at 378C. Fluorescence signals were detected using GloMax Discover System (Promega).
Plasmid and siRNA transfections
pHM-FLAG-eEF2K wild-type and K170M vectors were described previously. 22 siRNA scrambled (UUCUCCGAACGUGUCACGUdTdT), eEF2 (EHU047821) and eEF2K (EHU072281) were from Sigma-Aldrich. Plasmid and siRNA transfections were performed using lipofectamine 3000 (Thermo Fisher Scientific) following the manufacturer's instructions.
Immunohistochemical analysis and quantification
The tissue slides were first deparaffinized and then hydrated. After microwave antigen retrieval, endogenous peroxidase activity was blocked with incubation of the slides in methanol containing 3% H 2 O 2 , and nonspecific binding sites were blocked with 10% BSA. After serial incubation with primary antibody overnight at 48C, followed by SignalStainV R Boost IHC Detection Reagent (New England Biolabs, Herts, UK), the sections were developed in diaminobenzidine solution under a microscope and counterstained with hematoxylin.
Results
eEF2K promotes cancer cell migration and invasion
To assess the effect of eEF2K on cancer cell motility, we performed scratch wound-healing assays under a variety of conditions some of which stimulate eEF2K activity, and thus eEF2 phosphorylation, over a suitable time-period ( Figs ], 2-DG (2-deoxyglucose), a glucose analog that blocks glycolysis) treatment strongly induced eEF2 phosphorylation for at least 48 hr (Fig. 1a) . We noticed that inducing a shRNA against eEF2K prevented the phosphorylation of eEF2 and slowed down cell migration into the "wounded" area (Figs. 1b and 1c; Supporting Information Figs. S1b-S1e).
When cells were cultured in low glucose (5.5 mM) medium, the anti-migratory effect of knocking down eEF2K was more prominent than in cells treated with 2-DG alone, (Figs. 1b and 1c) . Inhibition of mTOR by AZD8055 23 or extracellular acidosis (pH 6.7), both of which conditions stimulate eEF2K activity (Supporting Information Fig.  S1a ) 13, 24 when cells are cultured in high glucose (25 mM) medium (Supporting Information Figs. S1b-S1e), had a greater effect than when cultured under control conditions. Therefore, the inhibitory effects of AZD8055 and extracellular acidosis on cell migration are likely to be mediated by other factors rather than elevated eEF2K activity. Levels of phosphorylated (P-) ribosomal protein S6 (rpS6) Ser240/Ser244 and P-PKB (protein kinase B, also termed Akt) Ser473 were monitored to assess mTORC1 and 2 signaling, 25, 26 respectively (Supporting Information Figs. S1a and S2d). To further test whether pharmacological inhibition of eEF2K affects cancer cell mobility, we treated A549 cells (Fig.  1d ) and breast cancer MDA-MB-231 cells ( Fig. 2a) with reported eEF2K inhibitors. On a cautionary note, some studies suggest that NH125 possesses off-target effects, 27, 28 A-484954 is more specific (albeit rather less potent). 27 We therefore also used a third previously characterized and chemically distinct eEF2K inhibitor, JAN-384. 18 Each of these inhibitors effectively reduced the speed of migration of A549 (Figs. 1e and 1f To extend these studies to analyze directly appropriate to tumor metastasis, we used the three-dimensional transwell migration/invasion system to assess the ability of cells to migrate through or "invade" an extracellular matrix. Either knocking down eEF2K by inducible shRNA in A549 cells (Figs. 1g-1j ) or pharmacologically inhibiting eEF2K in both A549 (Figs. 1g-1j ) and MDA-MB-231 (Figs. 2d-2g ) cells impaired the migratory and invasive capacities of these cells in these transwell assays. In addition, eEF2K knock-down or inhibition reduced the adhesion capacity of A549 (Figs. 1k and 1l) and MDA-MB-231 cells (Fig. 2h) .
In contrast, overexpressing wild-type FLAG-tagged eEF2K (but not the kinase-dead (K170M) 22 mutant) (Figs. 3a-3e) or knocking down eEF2 by siRNA (Figs. 3f-3j ) in A549 cells improved the scratch wound-healing and invasive capacities of A549 cells. Mitomycin C was added in all assays to rule out interference by possible effects on cell proliferation; this compound did not compromise cell viability (Supporting Information Fig. S5b ). These data suggest that genetically or pharmacologically inhibiting eEF2K impairs the mobility of cancer cells. Interestingly, however, in non-transformed cells such as MEFs, eEF2K knock-out not only failed to slow down "wound-healing," but actually accelerated migration into the "wounded" area (Supporting Information Fig. S2 ), although eEF2K
2/2 MEFs did show decreased invasiveness compared to their wild-type counterparts (Supporting Information Figs. S2i and S2j). Previously, several studies have reported a pro-survival role of eEF2K in cancer cells under stress. 9, 12, 13, 29 Importantly, under all experimental conditions we tested, intracellular energy and cell survival rates were unaltered upon eEF2K knock-down, as demonstrated by the end-point cell ATP and cytotoxicity assays (Supporting Information Figs. S4 and S5) . Thus, the effect of eEF2K on cell migration observed here does not reflect effects on cellular energy or survival. This raises the question, how does eEF2K, an inhibitor of translation elongation, promote cellular migration and invasion? eEF2K controls the translation of mRNAs encoding proteins involving in cell migration Although translation initiation is often considered as the rate-limiting step of protein synthesis, translation elongation can also indirectly regulate the expression rates of certain proteins. For example, the presence of rare codons positioned near the start codon delays the loading of additional 40 S subunits. 30 To investigate whether eEF2K contributes to the migratory ability of cancer cells by affecting the levels of specific proteins involving in the cell migration process, we cultured A549 cells carrying an IPTG-inducible shRNA directed toward the Eef2k mRNA in the presence or absence of IPTG and/or 2-DG, to further enhance eEF2K activation and eEF2 phosphorylation (Fig. 4a) . 29 We analyzed the steady-state proteome of these cells by label-free LC-HDMS E and identified 5,092 proteins in total (Supporting Information Table S3 ). Expression levels of most of these proteins were unchanged upon 2-DG or IPTG treatment (Supporting Information Fig. S6a ). However, we did identify 150 and 73 proteins as being decreased or increased (Fig. 4b-4d , Supporting Information Figs. S6 and S7) respectively upon eEF2K knock-down. Interestingly, 34 of the downregulated proteins are implicated in cell migration (Fig.  4e) . Among them, eight proteins are involved in integrin signaling (Figs. 4d and 4e) and thus in controlling cell-cell/cellextracellular matrix interactions and hence cell mobility. These are ACTN4 (actinin-a4), COL2A1 (collagen type II, a1), FLNB (filamin B), ITGA2 (integrin a2), ITGA3 (integrin a3), ITGA4 (integrin a4), LAMB4 (laminin subunit b4) and LAMC1 (laminin subunit g1).
Notably, we observed decreased levels of members of the kinesin family (KIF2A, KIF2B and KIF5A), molecular motors that move processively along microtubules to drive intracellular transport (Figs. 4d and 4e) . 32 In contrast, some other migration-related proteins, such as vimentin, were unaffected by eEF2K knock-down. Their expression is upregulated during EMT (epithelial-mesenchymal transition), whereby cells lose their polarized and adhesive phenotypes and gain motility and invasiveness; 33 ZO1 (Zonula occludens-1, also termed tight junction protein-1) is downregulated during EMT, 33 but was not affected by knockdown of eEF2K.
To further investigate how eEF2K regulates the expression of proteins involved in cell mobility, we cultured A549 cells in the absence or presence of 2-DG and/or IPTG and collected ribosomal fractions by centrifugation through sucrose gradients (Fig. 5a ). We observed a slight decrease in the proportion of ribosomes in translationally-active polysomal fractions vs. translationally-inactive sub-polysomal/monosomal fractions (P/M ratio) in cells where eEF2K was knocked down (Fig. 5b) , likely reflecting the expected acceleration of elongation and thus ribosomal "run-off" when eEF2K is knocked down. Consistent with recent findings, 34 eEF2 is mainly associated with inactive ribosomes, although this binding was unaffected by its phosphorylation status (Figs. 5c and 5d; Supporting Information Fig. S8 ). Importantly, upon eEF2K knock-down, the amounts of the mRNAs encoding integrins a2 and a3 (ITGA2 and ITGA3) that were associated with active polysomes decreased whereas their association with inactive sub-polysomal fractions rose (Figs. 5e and 5f ). In contrast, the distribution of the VIM mRNA, encoding vimentin, was unchanged (Fig.  5g) . The total levels of ITGA2, ITGA3 and VIM mRNAs were similar in control and eEF2K knock-down cells (Supporting Information Figs. S9a-S9c) . These data indicate that eEF2K positively controls the ribosomal association of certain cell migration-related mRNAs by shifting their mRNAs from sub-polysomal to active polysomal fractions. To confirm these findings, we measured cell surface ITGA2 expression levels in 2-DG-treated control or eEF2K knock-down A549 cells by flow cytometry analysis. Cell surface levels of ITGA2 were indeed reduced upon eEF2K knock-down, and of interest, 2-DG treatment (which induced eEF2 phosphorylation, i.e., eEF2K activity), increased ITGA2 protein expression (Figs. 5h and 5i) .
To complement these studies, we also tested the effect of pharmacological blockade of eEF2K on ITGA2 protein expression using the eEF2K inhibitors A-484954 27 and NH125, 35 both of which effectively prevented eEF2 phosphorylation in A549 and MDA-MB-231 cells (Supporting Information Fig. S10 ). All these eEF2K inhibitors reduced cell surface ITGA2 levels on A549 and MDA-MB-231 cells (Figs. 5j and 5k, Supporting Information Fig. S11) .
A recent in vitro study reported several novel eEF2K substrates; 36 among them, NDRG1 is implicated in cancer cell invasion and metastasis and was reported to be phosphorylated by eEF2K on Thr346, Thr356 and/or Thr366. [37] [38] [39] [40] However, we were unable to detect any phosphorylation of NDRG1 by eEF2K in vitro or on the phosphorylation of NDRG1 in cells (Supporting Information Figs. S12 and S13). As such, the stimulatory effect of eEF2K on cell migration and invasion is unlikely to be mediated through phosphorylation of NDRG1.
eEF2K inhibition prevents tumor metastasis and growth in vivo
To examine the effect of eEF2K inhibition on tumor metastasis and growth in vivo, we injected A549 cells into BALB/c nude mice in the presence of vehicle, A-484954 or NH125 (Unfortunately, the properties of JAN-384 make it unsuitable for use in vivo). These agents had no effect on mouse viability or weight (Supporting Information Fig. S14 ). As expected, NH125 and A-484954 each effectively inhibited the phosphorylation of eEF2, concomitant with a reduction in the levels of eEF2K (Fig. 6a) . Notably, eEF2K inhibitors greatly decreased the number of metastatic lung tumor nodules in these mice (Figs. 6b-6d ). This was associated with a reduction in the phosphorylation of eEF2 and of FAK (focal adhesion kinase) (Fig. 6e and Supporting Information Fig. S15) ; the latter is activated by integrin signaling. 41 These data strongly suggest that inhibiting eEF2K impairs tumor metastasis, probably at least in part due to decreased translation of mRNAs for integrins and other proteins involved in cell migration.
To further corroborate our findings using inhibitors of eEF2K, we considered it important to disable eEF2K genetically using shRNA-mediated knock-down. Accordingly, A549 cells were infected with lentiviruses expressing either nontargeting (shNT) or eEF2K (sheEF2K) shRNA. This caused substantial decreases in the levels of the EEF2K mRNA, and the eEF2K protein in A549 cells (Figs. 6f and 6g) as well as the phosphorylation of eEF2 in both cells and lung tissue of mice injected with A549 cells harboring the shRNA against eEF2K (Figs. 6g and 6h) . Analysis revealed reduced numbers of nodules in lungs of mice injected with shRNA-eEF2K A549 cells compared to mice injected with control A549 cells (Figs. 6i-6k ). Immunocytochemical analysis confirmed the expected reductions in eEF2K and p-eEF2 in lung sections for sheEF2K lung tissue compared to controls (Fig. 6l) . Taken together, our data provide additional evidence for a role for eEF2K in promoting primary tumor development, growth and metastasis in vivo.
Recently, it has been reported that eEF2K deficiency impairs aerobic glycolysis. 42 However, in both A549 and MDA-MB-231 cells, neither glycolytic capacity nor mitochondrial respiration was significantly altered upon knocking down or inhibiting eEF2K under our experimental conditions (Supporting Information Fig. S16 ). Thus the effects of eEF2K on cell migration, tumor growth and metastasis observed in our study are unlikely to involve changes in glycolysis or mitochondrial metabolism, and thus in cellular energy status.
Discussion
Metastasis is one of the distinguishing hallmarks of malignant cancers. Indeed, most deaths from cancer are due to metastatic disease. 1, 2 Although it is now clear that translation initiation can control the synthesis of specific proteins to aid cancer cell migration, [3] [4] [5] it was previously known whether translation elongation also plays roles in cancer cell mobility, and if so, what molecular mechanisms underlie this. A previous report showed that the eEF2K inhibitor A-484954 prevented PDGF-BB (platelet-derived growth factor subunit B homodimer)-induced vascular smooth muscle cell (VSMC) migration, although they also observed a drastic decrease in cell proliferation when cells were treated with A-484954. 43 Thus, the reported effect of A-484954 on VSMC migration largely reflected inhibition of cell proliferation.
Here, we provide a number of lines of evidence that eEF2K plays a crucial role in mediating cancer cell migration. This includes use of knockdown of eEF2K expression or pharmacological inhibition of its activity, and data showing that eEF2K regulates the expression of proteins involved in cell mobility and related signaling processes. Notably, in our study, the in vitro scratch wound-healing and transwell invasion assays were all performed in the presence of mitomycin C to eliminate any potential interference from altered cell proliferation. We also performed cellular ATP and cytotoxicity measurements and found no differences between treated and vehicle-treated cells. Therefore, we can conclude that eEF2K and (given eEF2 is its only known substrate) and hence control of translation elongation have a positive impact on cancer cell mobility independent of its effects, if any, on cell number and viability. However, although inhibition or loss of eEF2K had no adverse effect on cell viability in any of the migration or invasion assays tested in our study (Supporting Information Fig. S5 ), we cannot fully rule out the possibility that the inhibition or loss of eEF2K may still induce cell death in vivo which might contribute to the reduced "metastasis" observed in our study.
Our data show that the absence of eEF2K affects the cellular levels of a number of proteins, including several involved in processes linked to cell migration. Most importantly, we show that eEF2K promotes the association of specific mRNAs with polysomes, notably those for integrins A2 and A3. Thus, eEF2K favors the polysomal recruitment of these mRNAs, consistent with its ability to promote the steady-state levels of the corresponding proteins. These effects likely contribute to the positive role of eEF2K in cell migration. Our findings extend earlier data showing that eEF2K promotes the synthesis of cytoskeleton-associated proteins in neurons. 44 In particular, those data revealed effects on proteins associated with microtubules, while our present data also show that eEF2K modulates the levels of kinesins, which move cargoes along microtubules. This suggests a probable general role for eEF2K in modulating processes related to cellular dynamics (by promoting the translation of relevant subsets of mRNAs).
Notably, although some other molecular regulators of protein synthesis, such as mTORC1 and eIF4E may, as aforementioned, affect cancer cell migration, [3] [4] [5] they also support essential functions of healthy and normal cells. Inhibiting them may probably unavoidably cause unwanted secondary effects. In contrast, Eef2K knock-out mice are healthy and viable, 12 suggesting that eEF2K is unlikely to be essential to normal cell processes. Furthermore, loss of eEF2K did not impair the migration of (non-transformed) MEFs, in contrast to its strong effect in cancer cells. An ideal anti-cancer drug candidate for targeting tumor metastasis would not impair normal wound healing, and based on the results presented here, an eEF2K inhibitor appears to fit this key criterion.
Importantly, we provide the first evidence that pharmacological inhibition of eEF2K prevents tumor development, growth and metastasis in vivo. Thus, the development of specific eEF2K inhibitors with improved pharmacological properties may be valuable in the fight against cancer. However, it is also important to point out that, according to some reports, knocking-down eEF2K may actually promote tumor growth. 45, 46 Our data also suggest that the levels of expression of eEF2K may serve as a biological marker as to determine the cancer progression stage in patients. Indeed, in certain types of colorectal cancer and melanoma, eEF2K expression levels are higher in normal tissues compared to the cancer ones. 47 Therefore, future studies should also aim to determine whether eEF2K plays cell type-specific roles in different types of cancer, or whether its effect on cancer development is stage-dependent. In summary, our data add to the growing evidence that controlling elongation affects expression of specific proteins and show that, like translation initiation, control of elongation contributes to cancer cell biology. We demonstrate that eEF2K positively mediates cancer cell migration likely via the upregulation of relevant proteins, such as integrins and kinesins. Conversely, inhibiting eEF2K either in vitro or in vivo impedes cancer cell mobility in vitro and, more importantly for limiting metastasis, in vivo. High levels of eEF2K expression are associated with invasive tumors. Pharmacological blockade of eEF2K may serve as a promising therapy against the growth and progression of solid tumors.
